Premarket analyst action - healthcare

  • AAC Holdings (NASDAQ:AAC) initiated with Overweight rating and $11 (34% upside) price target by Cantor Fitzgerald.
  • BioScrip (NASDAQ:BIOS) upgraded to Buy with a $3.75 (30% upside) price target by SunTrust.
  • Cerner (NASDAQ:CERN) upgraded to Equal Weight with a $62 (flat) price target by Morgan Stanley.
  • Syros Pharmaceuticals (NASDAQ:SYRS) downgraded to Market Perform by JMP Securities.
  • Achillion Pharmaceuticals (NASDAQ:ACHN) downgraded to Neutral with a $5 (4% upside) price target by Baird citing doubts that PNH candidate ACH-4471 can compete with Alexion's Soliris.
  • Athersys (NASDAQ:ATHX) price target raised to $12 (875% upside) from $9 by Maxim Group after Q2 beat.
  • Agios Pharmaceuticals (NASDAQ:AGIO) price target raised to $72 (19% upside) from $54 citing recent approval of commercialization partner Celgene's IDHIFA (enasidenib) and plans for a Phase 3 study of AG-348 in adults with pyruvate kinase deficiency (PKD).
  • Amicus Therapeutics (NASDAQ:FOLD) price target raised to $17.50 (39% upside) from $12.50 by Chardan Capital citing Galafold progress in Fabry disease and positive data on ATB200/AT2221 in Pompe disease.
  • Aralez Pharmaceuticals (NASDAQ:ARLZ-OLD) price target lowered to $4 (257% upside) from $5.50 by Chardan after Q2 results.
  • Source: Bloomberg

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.